Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059946 | 0.81 | TP53 (0.50) | SMN1; SMN2HTTNAMPTACHETP53 | |
| SCHEMBL26484685 | 0.81 | NAMPT (0.52) | SMN1; SMN2TAS1R3TAS1R1HTTNAMPT | |
| SCHEMBL23077074 | 0.80 | ACHE (0.46) | SMN1; SMN2HTTACHETP53POLB | |
| SCHEMBL26484700 | 0.79 | ACHE (0.45) | SMN1; SMN2HTTACHETP53POLB | |
| SCHEMBL12043752 | 0.78 | MAPT (0.50) | SMN1; SMN2ACHETP53POLBGAA | |
| SCHEMBL12043753 | 0.77 | TP53 (0.49) | SMN1; SMN2ACHETP53POLBGAA | |
| SCHEMBL14745085 | 0.76 | ACHE (0.56) | SMN1; SMN2HTTACHEGAAMAPT | |
| SCHEMBL2819895 | 0.75 | ACHE (0.51) | SMN1; SMN2ACHETP53POLBGAA | |
| SCHEMBL8144515 | 0.75 | KCNJ1 (0.51) | SMN1; SMN2ACHETP53GAAMAPT | |
| SCHEMBL21792031 | 0.75 | KDM4E (0.56) | SMN1; SMN2ACHETP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | UPF1, HNRNPUL1, HNRNPUL2 | SMN1; SMN2 184/4885TAS1R3 3053/4885TAS1R1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.